
  
    
      
        Background_NNP
        The_DT cyclin-dependent_JJ kinase_NN inhibitor_NN p_NN 27_CD Kip_NNP 1_CD plays_VBZ an_DT
        important_JJ role_NN in_IN regulating_VBG cell_NN cycle_NN progression_NN by_IN
        inhibiting_VBG the_DT cyclin-_NN Cdk_NNP complexes_NNS responsible_JJ for_IN
        promoting_VBG the_DT transition_NN from_IN G_NNP 1_CD -_: phase_NN to_TO S-_NNP phase_NN [_NN 1_CD 2_CD ]_NN ._.
        In_IN normal_JJ cells_NNS ,_, p_NN 27_CD Kip_NNP 1_CD levels_NNS are_VBP high_JJ in_IN GO_NNP and_CC decrease_VB
        rapidly_RB in_IN late_JJ G_NNP 1_CD allowing_VBG entry_NN into_IN S-_NNP phase_NN [_NN 3_CD 4_CD ]_NN ._.
        p_NN 27_CD Kip_NNP 1_CD has_VBZ also_RB been_VBN implicated_VBN as_IN playing_VBG a_DT role_NN in_IN tumor_NN
        formation_NN and_CC progression_NN ._. 
        p_NN 27_CD Kip_NNP 1_CD knockout_NN mice_NNS display_VBP
        internal_JJ organ_NN hyperplasia_NN and_CC are_VBP highly_RB prone_JJ to_TO
        pituitary_JJ adenomas_NNS [_NN 5_CD 6_CD 7_CD ]_NN ._. In_IN human_JJ cancers_NNS ,_, such_JJ as_IN
        breast_NN [_NN 8_CD ]_NN ,_, prostate_NN [_NN 9_CD ]_NN ,_, colorectal_NN [_NN 10_CD ]_NN ,_, and_CC
        others_NNS ,_, low_JJ levels_NNS of_IN p_NN 27_CD Kip_NNP 1_CD expression_NN correlate_VBP with_IN
        decreased_VBN survival_NN rates_NNS ._. Since_IN mutations_NNS of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN are_VBP rare_JJ in_IN cancer_NN cells_NNS
        [_NN 11_CD ]_NN ,_, loss_NN of_IN p_NN 27_CD Kip_NNP 1_CD must_MD involve_VB changes_NNS in_IN the_DT
        mechanisms_NNS that_WDT control_NN its_PRP$ expression_NN ._.
        Changes_NNS in_IN the_DT levels_NNS of_IN cellular_JJ p_NN 27_CD Kip_NNP 1_CD are_VBP regulated_VBN
        by_IN multiple_JJ mechanisms_NNS ._. In_IN general_JJ ,_, transcriptional_NN control_NN
        of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN is_VBZ believed_VBN to_TO play_VB a_DT
        minor_JJ role_NN in_IN regulating_VBG p_NN 27_CD Kip_NNP 1_CD expression_NN ._. However_RB ,_,
        recent_JJ reports_NNS indicate_VBP that_DT transcription_NN of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN can_MD be_VB activated_VBN by_IN
        neuronal_NN differentiation_NN [_NN 12_CD ]_NN ,_, treatment_NN with_IN vitamin_NN D_NNP 3_CD
        [_NN 13_CD 14_CD ]_NN ,_, interferon_NN and_CC cytokines_NNS [_NN 15_CD 16_CD 17_CD ]_NN ,_, and_CC
        exposure_NN to_TO hypoxic_JJ conditions_NNS [_NN 18_CD ]_NN or_CC xenobiotics_NNS [_NN 19_CD ]_NN
        ._. Transcription_NNP of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN can_MD be_VB negatively_RB
        regulated_VBN by_IN growth_NN factors_NNS [_NN 20_CD ]_NN and_CC by_IN c-_NN Myc_NNP [_NN 21_CD ]_NN ._.
        Some_DT of_IN the_DT growth_NN factor_NN and_CC cytokine_NN effects_NNS on_IN 
        p_NN 27_CD Kip_NNP 1_CD transcription_NN may_MD be_VB mediated_JJ
        by_IN the_DT forkhead_NN family_NN of_IN transcription_NN factors_NNS that_WDT appear_VBP
        to_TO be_VB regulated_VBN downstream_JJ of_IN the_DT phosphatidylinositol_NN
        3_CD -_: kinase_NN signaling_VBG pathway_NN [_NN 22_CD 23_CD 24_CD 25_CD ]_NN ._. The_DT use_NN of_IN
        alternative_JJ promoters_NNS leading_VBG to_TO multiple_JJ transcription_NN
        start_NN sites_NNS ,_, as_IN reported_VBN here_RB ,_, suggests_VBZ an_DT additional_JJ type_NN
        of_IN transcriptional_NN control_NN ._.
        Post-transcriptional_NNP controls_NNS appear_VBP to_TO be_VB the_DT major_JJ
        regulatory_JJ mechanisms_NNS that_WDT determine_VBP the_DT levels_NNS of_IN p_NN 27_CD
        Kip_NNP 1_CD in_IN the_DT cell_NN [_NN 26_CD ]_NN ._. These_DT include_VBP ubiquitination_NN and_CC
        proteasomal_NN degradation_NN [_NN 27_CD ]_NN and_CC sequestration_NN and_CC
        mislocalization_NN [_NN 28_CD ]_NN of_IN the_DT p_NN 27_CD Kip_NNP 1_CD protein_NN ._. In_IN addition_NN ,_,
        changes_NNS in_IN the_DT rate_NN of_IN 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN translation_NN have_VBP been_VBN
        shown_VBN to_TO be_VB important_JJ in_IN regulating_VBG cellular_JJ p_NN 27_CD
        Kip_NNP 1_CD levels_NNS ._. The_DT rate_NN of_IN 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN translation_NN is_VBZ higher_JJR in_IN
        quiescent_JJ cells_NNS than_IN in_IN growth_NN factor_NN stimulated_VBN cells_NNS [_NN 3_CD
        ]_NN ._. p_NN 27_CD Kip_NNP 1_CD translation_NN is_VBZ also_RB enhanced_VBN during_IN
        differentiation_NN of_IN HL_NNP 60_CD cells_NNS [_NN 29_CD ]_NN ._.
        Recent_JJ studies_NNS have_VBP shown_VBN that_IN elements_NNS within_IN the_DT 5_CD '_POS
        untranslated_JJ region_NN (_( 5_CD '_POS -_: 
        UTR_NNP )_) of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN are_VBP able_JJ to_TO enhance_VB
        translational_NN efficiency_NN [_NN 30_CD 31_CD ]_NN and_CC several_JJ proteins_NNS
        that_WDT bind_NN to_TO the_DT 5_CD '_POS -_: 
        UTR_NNP have_VBP been_VBN identified_VBN [_NN 31_CD ]_NN ._. The_DT
        mouse_NN 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP has_VBZ recently_RB been_VBN shown_VBN to_TO be_VB
        able_JJ to_TO mediate_VB cap-independent_JJ initiation_NN of_IN translation_NN [_NN
        30_CD ]_NN ._. In_IN addition_NN ,_, a_DT U-_NNP rich_JJ element_NN within_IN the_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP may_MD be_VB involved_VBN in_IN regulating_VBG 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN stability_NN [_NN 32_CD ]_NN ._.
        Together_RB ,_, these_DT findings_NNS clearly_RB demonstrate_VBP the_DT importance_NN
        of_IN the_DT 5_CD '_POS -_: 
        UTR_NNP in_IN controlling_VBG cellular_JJ p_NN 27_CD
        Kip_NNP 1_CD levels_NNS ._. However_RB ,_, from_IN the_DT work_NN published_VBN to_TO date_NN it_PRP is_VBZ
        not_RB clear_JJ what_WP sequences_NNS constitute_VBP the_DT full_JJ 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP in_IN either_DT human_NN or_CC mouse_NN ._.
        The_DT 5_CD '_POS end_NN of_IN the_DT 
        UTR_NNP is_VBZ determined_VBN by_IN the_DT site_NN of_IN
        transcription_NN initiation_NN and_CC several_JJ papers_NNS have_VBP reported_VBN
        putative_JJ 
        p_NN 27_CD Kip_NNP 1_CD transcription_NN initiation_NN
        sites_NNS ._. In_IN mouse_NN ,_, Kwon_NNP et_CC al_NN ._. [_NN 33_CD ]_NN reported_VBD a_DT major_JJ
        transcription_NN start_NN site_NN 200_CD nucleotides_NNS upstream_RB of_IN the_DT
        AUG_NNP start_NN codon_NN ._. They_PRP also_RB reported_VBD a_DT second_JJ transcription_NN
        initiation_NN site_NN 253_CD nucleotides_NNS upstream_RB of_IN the_DT start_NN
        codon_NN ._. In_IN contrast_NN ,_, Zhang_NNP and_CC Lin_NNP [_NN 34_CD ]_NN reported_VBD that_IN the_DT
        mouse_NN 
        p_NN 27_CD Kip_NNP 1_CD transcription_NN start_NN site_NN is_VBZ
        ~_NN 500_CD nucleotides_NNS upstream_RB of_IN the_DT start_NN codon_NN ._. They_PRP found_VBD no_DT
        evidence_NN for_IN the_DT downstream_JJ initiation_NN sites_NNS reported_VBN by_IN
        Kwon_NNP et_CC al_NN ._. [_NN 33_CD ]_NN ._. The_DT gene_NN sequences_NNS upstream_RB of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD start_VB codon_NN ,_, including_VBG the_DT
        putative_JJ promoter_NN regions_NNS ,_, are_VBP highly_RB conserved_JJ between_IN
        mouse_NN and_CC human_JJ ._. However_RB ,_, it_PRP has_VBZ been_VBN reported_VBN that_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD transcription_NN start_NN site_NN in_IN
        human_JJ cells_NNS is_VBZ only_RB 153_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP
        start_NN codon_NN [_NN 31_CD 35_CD ]_NN ._. In_IN contrast_NN to_TO these_DT findings_NNS ,_, Ito_NNP
        et_CC al_NN ._. [_NN 36_CD ]_NN reported_VBD multiple_JJ start_NN sites_NNS in_IN the_DT region_NN
        from_IN 403_CD to_TO 479_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP as_RB well_RB as_IN
        minor_JJ sites_NNS 280_CD and_CC 273_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP ._.
        Thus_RB ,_, for_IN both_DT mouse_NN and_CC human_JJ 
        p_NN 27_CD Kip_NNP 1_CD genes_NNS there_RB are_VBP discrepancies_NNS
        between_IN the_DT reported_VBN transcription_NN start_NN sites_NNS ._. In_IN
        addition_NN ,_, despite_IN the_DT high_JJ level_NN of_IN conservation_NN in_IN 
        p_NN 27_CD Kip_NNP 1_CD gene_NN sequences_NNS ,_, the_DT reports_NNS
        in_IN the_DT literature_NN show_NN no_DT correlation_NN between_IN mouse_NN and_CC
        human_JJ initiation_NN sites_NNS ,_, which_WDT would_MD result_VB in_IN very_RB
        different_JJ 5_CD '_POS -_: 
        UTRs_NNP in_IN the_DT final_JJ 
        p_NN 27_CD Kip_NNP 1_CD mRNAs_NNS ._.
        Given_VBN the_DT importance_NN of_IN the_DT 5_CD '_POS -_: 
        UTR_NNP in_IN governing_VBG p_NN 27_CD Kip_NNP 1_CD levels_NNS and_CC
        the_DT disparity_NN among_IN the_DT reports_NNS described_VBD above_IN ,_, we_PRP felt_VBD it_PRP
        necessary_JJ to_TO further_VB investigate_VB the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN transcription_NN initiation_NN
        sites_NNS ._. We_PRP have_VBP used_VBN a_DT method_NN that_WDT accurately_RB identifies_VBZ the_DT
        capped_VBN 5_CD '_POS -_: end_NN of_IN mRNAs_NNS together_RB with_IN RNase_NNP protection_NN
        assays_NNS ._. Our_PRP$ data_NNS indicate_VBP that_IN the_DT major_JJ transcription_NN
        start_NN site_NN is_VBZ at_IN exactly_RB the_DT same_JJ sequence_NN in_IN mouse_NN and_CC
        human_JJ cells_NNS and_CC that_DT transcription_NN initiation_NN from_IN this_DT
        site_NN produces_VBZ a_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP of_IN 502_CD nucleotides_NNS in_IN mouse_NN and_CC
        472_CD nucleotides_NNS in_IN human_NN ._. These_DT findings_NNS represent_VBP
        important_JJ sequence_NN information_NN relevant_JJ to_TO studies_NNS being_VBG
        done_VBN on_IN both_DT transcriptional_NN and_CC post-transcriptional_JJ
        control_NN of_IN p_NN 27_CD Kip_NNP 1_CD levels_NNS ._.
      
      
        Results_NNS
        
          Determination_NNP of_IN transcription_NN initiation_NN sites_NNS
          using_VBG RNA_NNP ligase-mediated_JJ rapid_JJ amplification_NN of_IN 5_CD '_POS cDNA_NN
          ends_VBZ (_( 5_CD '_POS RLM-RACE_NNP )_)
          To_TO identify_VB transcription_NN initiation_NN sites_NNS ,_, RLM-RACE_NNP
          was_VBD performed_VBN ._. This_DT method_NN has_VBZ a_DT major_JJ advantage_NN over_IN
          other_JJ methods_NNS of_IN mapping_NN transcription_NN start_NN sites_NNS ,_, such_JJ
          as_IN primer_NN extension_NN ,_, nuclease_NN protection_NN assays_NNS ,_, or_CC
          traditional_JJ 5_CD '_POS RACE_NNP ,_, in_IN that_DT only_RB authentic_JJ capped_VBD 5_CD '_POS
          ends_NNS of_IN mRNAs_NNS are_VBP detected_VBN ._. The_DT first_JJ step_NN in_IN RLM-RACE_NNP is_VBZ
          treatment_NN of_IN the_DT RNA_NNP sample_NN with_IN phosphatase_NN ._. This_DT
          removes_VBZ the_DT 5_CD '_POS phosphate_NN from_IN incomplete_JJ mRNA_NN fragments_NNS
          and_CC from_IN non-m_JJ RNAs_NNP eliminating_VBG their_PRP$ ability_NN to_TO
          participate_VB in_IN subsequent_JJ ligation_NN reactions_NNS ._. In_IN the_DT
          second_JJ step_NN of_IN the_DT procedure_NN the_DT 7_CD -_: methylguanosine_NN cap_NN of_IN
          mRNAs_NNS is_VBZ removed_VBN using_VBG a_DT pyrophosphatase_NN that_WDT leaves_VBZ a_DT 5_CD '_POS
          phosphate_NN group_NN ._. These_DT full-length_JJ decapped_JJ mRNAs_NNS are_VBP
          thus_RB the_DT only_RB RNA_NNP molecules_NNS that_WDT can_MD be_VB ligated_JJ to_TO an_DT RNA_NNP
          oligonucleotide_NN adapter_NN in_IN the_DT next_JJ step_NN of_IN the_DT
          procedure_NN ._. Finally_RB ,_, the_DT RNAs_NNP are_VBP reverse_VB transcribed_JJ
          followed_VBN by_IN PCR_NNP amplification_NN using_VBG a_DT gene-specific_JJ
          primer_NN and_CC a_DT primer_NN homologous_RB to_TO the_DT RNA_NNP oligonucleotide_NN
          adapter_NN ._.
          This_DT procedure_NN was_VBD carried_VBN out_IN using_VBG total_JJ RNA_NNP from_IN
          the_DT mouse_NN NIH_NNP 3_CD T_NN 3_CD cell_NN line_NN ,_, the_DT non-transformed_JJ human_JJ
          MRC_NNP 5_CD cell_NN line_NN ,_, and_CC the_DT human_JJ breast_NN cancer_NN line_NN MCF_NNP 7_CD ._.
          The_DT initial_JJ PCR_NNP was_VBD performed_VBN using_VBG a_DT primer_NN
          complimentary_JJ to_TO the_DT 
          p_NN 27_CD Kip_NNP 1_CD mRNA_NN sequence_NN just_RB upstream_RB
          of_IN the_DT AUG_NNP start_NN codon_NN (_( see_VB Figs_NNP ._. 1_LS Band_NNP 2_CD C_NNP )_) together_RB with_IN
          the_DT adapter_NN primer_NN ._. Nested_NNP PCR_NNP was_VBD then_RB performed_VBN using_VBG
          the_DT first_JJ PCR_NNP product_NN as_IN a_DT template_NN and_CC the_DT gene_NN specific_JJ
          primers_NNS indicated_VBD in_IN Figs_NNP ._. 1_LS Band_NNP 2_CD C_NNP ._. The_DT nested_JJ PCR_NNP
          products_NNS were_VBD then_RB cloned_VBN and_CC sequenced_JJ ._.
          In_IN mouse_NN ,_, three_CD bands_NNS were_VBD obtained_VBN after_IN the_DT 5_CD '_POS RACE_NNP
          nested_JJ PCR_NNP reaction_NN (_( Fig_NNP ._. 1_LS A_DT )_) with_IN estimated_VBN sizes_NNS of_IN
          200_CD ,_, 250_CD ,_, and_CC 500_CD base_NN pairs_NNS ,_, with_IN the_DT 500_CD base_NN pair_NN band_NN
          being_VBG the_DT most_RBS intense_JJ ._. Cloning_NNP and_CC sequencing_VBG of_IN these_DT
          PCR_NNP products_NNS revealed_VBD three_CD different_JJ DNA_NNP sequences_NNS ,_, each_DT
          preceded_VBN by_IN a_DT sequence_NN corresponding_JJ to_TO the_DT RNA_NNP
          oligonucleotide_NN adapter_NN and_CC thus_RB representing_VBG authentic_JJ
          cap_NN sites_NNS ._. These_DT sites_NNS map_VBP to_TO 200_CD ,_, 253_CD ,_, and_CC 502_CD
          nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP translation_NN start_NN codon_NN
          in_IN the_DT mouse_NN 
          p_NN 27_CD Kip_NNP 1_CD gene_NN (_( Fig_NNP ._. 1_LS B_NNP )_) ._.
          When_WRB the_DT RLM-RACE_NNP procedure_NN was_VBD performed_VBN using_VBG RNA_NNP
          from_IN the_DT non-transformed_JJ human_JJ MRC_NNP 5_CD cell_NN line_NN a_DT single_JJ
          major_JJ band_NN of_IN approximately_RB 480_CD base_NN pairs_NNS was_VBD observed_VBN
          after_IN the_DT initial_JJ PCR_NNP reaction_NN (_( Fig_NNP ._. 2_LS A_DT )_) ._. With_IN the_DT human_JJ
          MCF_NNP 7_CD breast_NN cancer_NN cell_NN line_NN two_CD bands_NNS of_IN approximately_RB
          480_CD and_CC 400_CD base_NN pairs_NNS were_VBD observed_VBN (_( Fig_NNP ._. 2_LS A_DT )_) ._. Nested_NNP
          PCR_NNP confirmed_VBD these_DT bands_NNS and_CC revealed_VBD several_JJ faint_JJ
          bands_NNS of_IN various_JJ sizes_NNS (_( Fig_NNP ._. 2_LS B_NNP )_) ._. Direct_NNP cloning_VBG of_IN the_DT
          RLM-RACE_NNP products_NNS followed_VBN by_IN sequencing_VBG demonstrated_VBN
          that_IN the_DT major_JJ mRNA_NN cap_NN site_NN in_IN MRC_NNP 5_CD cells_NNS is_VBZ 472_CD
          nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP (_( Fig_NNP ._. 2_LS C_NNP )_) ._. For_IN MCF_NNP 7_CD ,_, cap_NN
          sites_NNS were_VBD observed_VBN at_IN 472_CD and_CC 403_CD nucleotides_NNS upstream_RB
          of_IN the_DT AUG_NNP start_NN codon_NN ._.
          By_IN gel_NN purifying_VBG DNA_NNP fragments_NNS from_IN the_DT faint_JJ bands_NNS
          obtained_VBN after_IN the_DT nested_JJ PCR_NNP reactions_NNS and_CC then_RB
          reamplifying_VBG ,_, it_PRP was_VBD possible_JJ to_TO obtain_VB additional_JJ
          clones_NNS ._. These_DT presumably_RB correspond_VB to_TO minor_JJ start_NN sites_NNS
          that_WDT map_NN to_TO 677_CD ,_, 316_CD ,_, and_CC 289_CD nucleotides_NNS upstream_RB of_IN the_DT
          
          p_NN 27_CD Kip_NNP 1_CD start_VB codon_NN in_IN MCF_NNP 7_CD cells_NNS ._.
          Using_VBG this_DT procedure_NN for_IN MRC_NNP 5_CD cells_NNS we_PRP were_VBD able_JJ to_TO
          detect_VB a_DT minor_JJ cap_NN site_NN 403_CD nucleotides_NNS upstream_RB of_IN the_DT
          AUG_NNP ._.
        
        
          Determination_NNP of_IN transcription_NN initiation_NN sites_NNS
          using_VBG ribonuclease_NN protection_NN
          The_DT RLM-RACE_NNP procedure_NN identifies_VBZ authentic_JJ
          transcription_NN start_NN sites_NNS but_CC does_VBZ not_RB provide_VB a_DT
          quantitative_JJ measure_NN of_IN the_DT efficiency_NN at_IN which_WDT the_DT
          various_JJ sites_NNS are_VBP used_VBN ._. To_TO verify_VB the_DT results_NNS of_IN the_DT
          RLM-RACE_NNP and_CC to_TO provide_VB a_DT measure_NN of_IN transcription_NN start_NN
          site_NN usage_NN an_DT RNase_NNP protection_NN assay_NN was_VBD employed_VBN ._.
          Labeled_NNP antisense_NN RNA_NNP probes_NNS were_VBD made_VBN by_IN in_IN vitro_NN
          transcription_NN using_VBG the_DT cDNA_NN sequence_NN of_IN the_DT most_RBS
          abundant_JJ ,_, longer_JJR transcripts_NNS identified_VBN by_IN 5_CD '_POS RLM-RACE_NNP as_IN
          a_DT template_NN ._. The_DT human_JJ probe_NN was_VBD 535_CD nucleotides_NNS in_IN
          length_NN ,_, consisting_VBG of_IN 
          p_NN 27_CD Kip_NNP 1_CD sequences_NNS from_IN 17_CD to_TO 472_CD
          nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP with_IN the_DT remaining_VBG 79_CD
          nucleotides_NNS derived_VBN from_IN non-_NN 
          p_NN 27_CD Kip_NNP 1_CD sequences_NNS ._. The_DT mouse_NN probe_NN
          was_VBD 565_CD nucleotides_NNS in_IN length_NN and_CC included_VBD 
          p_NN 27_CD Kip_NNP 1_CD sequences_NNS from_IN 17_CD to_TO 502_CD
          nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP ._. The_DT labeled_VBN probes_NNS were_VBD
          hybridized_JJ with_IN total_JJ RNA_NNP from_IN various_JJ sources_NNS followed_VBN
          by_IN digestion_NN with_IN RNase_NNP and_CC analysis_NN of_IN the_DT protected_VBN
          RNAs_NNP on_IN denaturing_VBG acrylamide_NN gels_NNS ._.
          Using_VBG either_CC NIH_NNP 3_CD T_NN 3_CD (_( Fig_NNP ._. 3_LS A_DT )_) or_CC mouse_NN liver_NN (_( Fig_NNP ._.
          3_LS B_NNP )_) RNA_NNP for_IN the_DT RNase_NNP protection_NN assay_NN resulted_VBD in_IN a_DT
          single_JJ predominant_NN band_NN with_IN an_DT estimated_VBN size_NN of_IN 480_CD
          nucleotides_NNS (_( Figs_NNP ._. 3_LS Aand_NNP 3_CD B_NNP ,_, arrows_NNS )_) ._. This_DT corresponds_NNS to_TO
          the_DT distal_NN cap_NN site_NN detected_VBN by_IN RLM-RACE_NNP 502_CD nucleotides_NNS
          upstream_RB of_IN the_DT AUG_NNP ._. Very_RB faint_JJ bands_NNS of_IN approximately_RB
          190_CD and_CC 230_CD nucleotides_NNS (_( Figs_NNP ._. 3_LS Aand_NNP 3_CD B_NNP ,_, brackets_NNS )_) were_VBD
          also_RB detected_VBN and_CC these_DT correspond_VB to_TO the_DT other_JJ two_CD cap_NN
          sites_NNS mapped_VBN by_IN RLM-RACE_NNP ._. Using_VBG NIH_NNP 3_CD T_NN 3_CD RNA_NNP ,_, an_DT
          additional_JJ faint_JJ band_NN of_IN approximately_RB 350_CD nucleotides_NNS
          (_( Fig_NNP ._. 3_LS A_DT ,_, arrowhead_NN )_) was_VBD detected_VBN ._. This_DT band_NN does_VBZ not_RB
          correspond_VB to_TO any_DT known_VBN transcription_NN start_NN site_NN ._. The_DT
          various_JJ protected_VBN fragments_NNS were_VBD quantified_VBN by_IN
          densitometry_NN ._. After_IN correction_NN for_IN length_NN ,_, the_DT major_JJ band_NN
          at_IN ~_NN 480_CD nucleotides_NNS represents_VBZ ~_NN 50_CD ._. 6_CD %_NN of_IN p_NN 27_CD Kip_NNP 1_CD mRNAs_NNS
          in_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS and_CC 81_CD ._. 25_CD %_NN in_IN mouse_NN liver_NN ._. The_DT other_JJ
          protected_VBN bands_NNS represent_VBP approximately_RB equal_JJ proportions_NNS
          of_IN the_DT remaining_VBG p_NN 27_CD Kip_NNP 1_CD mRNA_NN population_NN ._.
          RNase_NNP protection_NN assays_NNS were_VBD performed_VBN using_VBG RNA_NNP from_IN
          three_CD separate_JJ human_JJ cell_NN lines_NNS ,_, MRC_NNP 5_CD ,_, MCF_NNP 7_CD ,_, and_CC BT_NNP 20_CD ._.
          For_IN all_DT three_CD lines_NNS a_DT single_JJ band_NN of_IN approximately_RB 450_CD
          nucleotides_NNS was_VBD observed_VBN (_( Fig_NNP ._. 4_LS ,_, arrow_NN )_) ._. This_DT
          corresponds_NNS to_TO the_DT major_JJ transcription_NN initiation_NN site_NN
          472_CD nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP as_IN identified_VBN by_IN
          RLM-RACE_NNP ._.
        
      
      
        Conclusions_NNP
        In_IN mouse_NN ,_, it_PRP was_VBD previously_RB reported_VBN that_IN the_DT major_JJ
        transcription_NN initiation_NN site_NN for_IN 
        p_NN 27_CD Kip_NNP 1_CD is_VBZ 200_CD nucleotides_NNS upstream_RB
        of_IN the_DT start_NN codon_NN with_IN a_DT minor_JJ start_NN site_NN 253_CD nucleotides_NNS
        upstream_RB of_IN the_DT ATG_NNP [_NN 33_CD ]_NN ._. We_PRP also_RB detected_VBD transcription_NN
        start_NN sites_NNS 200_CD and_CC 253_CD nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP but_CC
        have_VBP shown_VBN that_IN these_DT are_VBP only_RB rarely_RB used_VBN ._. The_DT RLM-RACE_NNP
        and_CC RNase_NNP protection_NN assays_NNS described_VBD here_RB show_NN that_IN the_DT
        overwhelming_JJ majority_NN of_IN mouse_NN 
        p_NN 27_CD Kip_NNP 1_CD transcripts_NNS are_VBP initiated_VBN at_IN
        a_DT position_NN 502_CD nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP ._. This_DT is_VBZ
        true_JJ for_IN both_DT mouse_NN liver_NN and_CC NIH_NNP 3_CD T_NN 3_CD cells_NNS ._. Zhang_NNP and_CC Lin_NNP
        [_NN 34_CD ]_NN ,_, using_VBG nuclease_NN protection_NN assays_NNS ,_, estimated_VBD the_DT
        mouse_NN 
        p_NN 27_CD Kip_NNP 1_CD start_VB site_NN to_TO be_VB 495_CD
        nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP start_NN codon_NN ._. Our_PRP$ results_NNS
        agree_VBP with_IN these_DT investigators_NNS but_CC precisely_RB position_VB the_DT
        start_NN site_NN 502_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP ._.
        In_IN human_JJ cell_NN lines_NNS ,_, the_DT major_JJ transcription_NN initiation_NN
        site_NN is_VBZ 472_CD nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP ._. Both_DT RNase_NNP
        protection_NN assays_NNS and_CC RLM-RACE_NNP (_( Figs_NNP ._. 2_LS and_CC 4_LS )_) demonstrate_VB
        this_DT ._. This_DT site_NN exactly_RB equates_VBZ to_TO the_DT major_JJ transcription_NN
        start_NN site_NN in_IN mouse_NN (_( Fig_NNP ._. 5_LS )_) ._. Using_VBG RLM-RACE_NNP we_PRP were_VBD also_RB
        able_JJ to_TO detect_VB minor_JJ cap_NN sites_NNS in_IN human_JJ cells_NNS ._. An_DT
        initiation_NN site_NN 403_CD nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP was_VBD
        easily_RB identified_VBN in_IN MCF_NNP 7_CD human_JJ breast_NN cancer_NN cells_NNS (_( Fig_NNP ._.
        2_LS )_) and_CC a_DT significant_JJ portion_NN of_IN the_DT initial_JJ clones_NNS were_VBD
        derived_VBN from_IN RNAs_NNP capped_VBD at_IN this_DT site_NN ._. In_IN contrast_NN ,_, 100_CD %_NN of_IN
        the_DT initial_JJ clones_NNS from_IN the_DT RLM-RACE_NNP procedure_NN using_VBG the_DT
        non-transformed_JJ human_JJ MRC_NNP 5_CD cell_NN line_NN were_VBD from_IN products_NNS
        capped_VBD 472_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP ._. By_IN gel_NN
        purification_NN and_CC reamplification_NN we_PRP were_VBD able_JJ to_TO detect_VB
        additional_JJ cap_NN sites_NNS 677_CD ,_, 316_CD ,_, and_CC 289_CD nucleotides_NNS upstream_RB
        of_IN the_DT AUG_NNP ._. However_RB ,_, these_DT can_MD only_RB be_VB very_RB minor_JJ start_NN
        sites_NNS since_IN they_PRP were_VBD rarely_RB observed_VBN by_IN RLM-RACE_NNP and_CC were_VBD
        not_RB detected_VBN by_IN RNase_NNP protection_NN assays_NNS ._. Using_VBG an_DT RLM-RACE_NNP
        procedure_NN similar_JJ to_TO that_DT used_VBD for_IN this_DT study_NN ,_, Ito_NNP et_CC al_NN ._. [_NN
        36_CD ]_NN mapped_VBN a_DT cluster_NN of_IN transcription_NN start_NN sites_NNS
        surrounding_VBG nucleotide_NN 472_CD upstream_RB of_IN the_DT ATG_NNP ._. However_RB ,_,
        their_PRP$ data_NNS did_VBD not_RB demonstrate_VB which_WDT site_NN within_IN this_DT
        cluster_NN served_VBD as_IN the_DT major_JJ initiation_NN site_NN ._.
        In_IN another_DT study_NN the_DT transcription_NN initiation_NN site_NN for_IN
        the_DT human_JJ 
        p_NN 27_CD Kip_NNP 1_CD gene_NN was_VBD reported_VBN to_TO be_VB 153_CD
        nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP [_NN 31_CD 35_CD ]_NN ._. The_DT experiments_NNS
        reported_VBD here_RB do_VBP not_RB support_VB these_DT findings_NNS ._. Using_VBG
        RLM-RACE_NNP ,_, a_DT faint_JJ band_NN of_IN approximately_RB 150_CD base_NN pairs_NNS
        could_MD be_VB observed_VBN after_IN nested_JJ PCR_NNP (_( Fig_NNP ._. 2_LS A_DT )_) ,_, but_CC we_PRP were_VBD
        unable_JJ to_TO clone_NN an_DT authentic_JJ RACE_NNP product_NN equating_VBG to_TO a_DT
        start_NN site_NN 153_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP ._. In_IN
        addition_NN ,_, no_DT bands_NNS corresponding_JJ to_TO a_DT start_NN site_NN at_IN this_DT
        position_NN were_VBD detected_VBN by_IN RNase_NNP protection_NN assays_NNS
        indicating_VBG that_IN ,_, if_IN there_EX is_VBZ a_DT transcriptional_NN start_NN site_NN
        at_IN 153_CD ,_, it_PRP is_VBZ extremely_RB rarely_RB used_VBN in_IN any_DT of_IN the_DT cell_NN
        lines_NNS that_IN we_PRP tested_VBD ._. The_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP is_VBZ predicted_VBN to_TO have_VB extensive_JJ
        secondary_JJ structure_NN [_NN 31_CD ]_NN ._. It_PRP is_VBZ possible_JJ that_IN this_DT could_MD
        interfere_VB with_IN primer_NN extension_NN analysis_NN ,_, which_WDT was_VBD used_VBN by_IN
        Minami_NNP et_CC al_NN ._. [_NN 35_CD ]_NN to_TO map_VB the_DT putative_JJ transcription_NN
        initiation_NN site_NN in_IN human_JJ cells_NNS ._. It_PRP is_VBZ also_RB possible_JJ that_IN
        differences_NNS exist_VBP between_IN the_DT cell_NN types_NNS used_VBN here_RB and_CC
        those_DT used_VBN in_IN previous_JJ reports_NNS ._. However_RB ,_, this_DT is_VBZ unlikely_JJ
        since_IN we_PRP observed_VBD exactly_RB the_DT same_JJ results_NNS with_IN three_CD
        separate_JJ human_JJ cell_NN lines_NNS ._.
        Both_DT the_DT mouse_NN and_CC human_JJ 
        p_NN 27_CD Kip_NNP 1_CD promoter_NN regions_NNS have_VBP
        previously_RB been_VBN characterized_VBN using_VBG reporter_NN gene_NN
        constructs_NNS ._. All_DT of_IN the_DT constructs_NNS that_WDT have_VBP significant_JJ
        levels_NNS of_IN promoter_NN activity_NN contain_VBP the_DT major_JJ
        transcriptional_NN start_NN sites_NNS identified_VBN in_IN this_DT study_NN [_NN 33_CD
        34_CD 35_CD 36_CD ]_NN ._. Mouse_NNP 
        p_NN 27_CD Kip_NNP 1_CD reporter_NN constructs_NNS
        containing_VBG ~_NN 500_CD base_NN pairs_NNS upstream_RB of_IN the_DT ATG_NNP start_NN codon_NN
        had_VBD virtually_RB no_DT activity_NN [_NN 33_CD 34_CD ]_NN ._. Similarly_RB a_DT human_JJ 
        p_NN 27_CD Kip_NNP 1_CD reporter_NN construct_VB containing_VBG
        435_CD base_NN pairs_NNS upstream_RB of_IN the_DT ATG_NNP was_VBD inactive_JJ [_NN 35_CD ]_NN ._.
        Our_PRP$ data_NNS indicate_VBP that_IN this_DT is_VBZ because_IN these_DT constructs_NNS did_VBD
        not_RB carry_VB the_DT major_JJ transcription_NN initiation_NN sites_NNS or_CC the_DT
        promoter_NN sequences_NNS necessary_JJ to_TO position_VB the_DT transcription_NN
        complex_JJ ._. In_IN this_DT regard_NN ,_, it_PRP is_VBZ noteworthy_JJ that_IN the_DT major_JJ
        transcription_NN start_NN site_NN for_IN both_DT mouse_NN and_CC human_NN is_VBZ
        positioned_VBN ~_NN 30_CD base_NN pairs_NNS downstream_JJ of_IN an_DT AT-rich_NNP element_NN
        that_WDT may_MD serve_VB as_IN a_DT TATA_NNP box_NN ._. This_DT element_NN in_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN (_( TTTAAT_NNP )_) matches_VBZ the_DT
        consensus_NN TATA_NNP box_NN sequence_NN (_( TATAA_NNP /_NN TAA_NNP /_NN T_NN )_) at_IN 6_CD out_IN of_IN 7_CD
        positions_NNS ._.
        It_PRP has_VBZ been_VBN shown_VBN that_DT expression_NN of_IN 
        p_NN 27_CD Kip_NNP 1_CD is_VBZ controlled_VBN at_IN the_DT
        translational_NN level_NN [_NN 3_CD 26_CD 29_CD ]_NN and_CC that_IN the_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP is_VBZ able_JJ to_TO mediate_VB enhanced_JJ
        translation_NN rates_NNS [_NN 31_CD ]_NN ._. In_IN addition_NN ,_, it_PRP was_VBD recently_RB
        reported_VBN that_IN the_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP has_VBZ an_DT internal_JJ ribosome_NN entry_NN
        site_NN that_WDT allows_VBZ cap-independent_JJ initiation_NN of_IN translation_NN
        [_NN 30_CD ]_NN ._. However_RB ,_, none_NN of_IN these_DT reports_NNS have_VBP utilized_JJ the_DT
        full_JJ 5_CD '_POS -_: 
        UTR_NNP that_IN results_NNS from_IN transcription_NN
        initiation_NN at_IN the_DT major_JJ start_NN site_NN ._. The_DT longest_JJS fragments_NNS
        of_IN the_DT 
        p_NN 27_CD Kip_NNP 15_CD '_POS -_: 
        UTR_NNP that_WDT have_VBP been_VBN analyzed_VBN include_VBP
        only_RB the_DT first_JJ 153_CD nucleotides_NNS upstream_RB of_IN the_DT AUG_NNP for_IN
        human_JJ [_NN 31_CD ]_NN and_CC 217_CD nucleotides_NNS for_IN mouse_NN [_NN 30_CD ]_NN ._. It_PRP is_VBZ
        very_RB likely_JJ that_IN the_DT additional_JJ ~_NN 300_CD nucleotides_NNS at_IN the_DT 5_CD '_POS
        end_NN of_IN the_DT major_JJ 
        p_NN 27_CD Kip_NNP 1_CD transcript_NN ,_, as_IN reported_VBN here_RB ,_,
        will_MD play_VB an_DT important_JJ role_NN in_IN regulating_VBG p_NN 27_CD
        Kip_NNP 1_CD expression_NN ._. It_PRP will_MD therefore_RB be_VB necessary_JJ to_TO
        re-examine_VB translational_NN control_NN of_IN 
        p_NN 27_CD Kip_NNP 1_CD in_IN the_DT context_NN of_IN its_PRP$ full_JJ
        5_CD '_POS -_: 
        UTR_NNP ._. 
        The_DT data_NNS presented_VBN here_RB show_NN that_IN ,_, although_IN there_EX is_VBZ a_DT
        single_JJ major_JJ site_NN ,_, there_EX are_VBP also_RB alternative_JJ transcription_NN
        initiation_NN sites_NNS for_IN both_DT mouse_NN and_CC human_JJ 
        p_NN 27_CD Kip_NNP 1_CD ._. This_DT adds_VBZ a_DT new_JJ dimension_NN
        to_TO studies_NNS on_IN 
        p_NN 27_CD Kip_NNP 1_CD expression_NN ._. One_CD interesting_JJ
        possibility_NN is_VBZ that_IN different_JJ start_NN sites_NNS may_MD be_VB used_VBN at_IN
        different_JJ points_NNS in_IN the_DT cell_NN cycle_NN or_CC during_IN cellular_JJ
        differentiation_NN ._. It_PRP is_VBZ known_VBN that_DT 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN levels_NNS stay_VBP relatively_RB
        steady_JJ throughout_IN the_DT cell_NN cycle_NN ._. However_RB ,_, usage_NN of_IN various_JJ
        transcription_NN start_NN sites_NNS could_MD be_VB regulated_VBN differently_RB ._.
        This_DT might_MD affect_VB the_DT length_NN of_IN the_DT 5_CD '_POS -_: 
        UTR_NNP and_CC thus_RB translation_NN of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD mRNA_NN ._. Additional_JJ studies_NNS will_MD
        need_VB to_TO be_VB done_VBN to_TO determine_VB if_IN and_CC when_WRB different_JJ
        transcription_NN start_NN sites_NNS are_VBP used_VBN ._.
        The_DT region_NN of_IN the_DT 
        p_NN 27_CD Kip_NNP 1_CD gene_NN upstream_RB of_IN the_DT ATG_NNP
        start_NN codon_NN is_VBZ highly_RB conserved_JJ in_IN mouse_NN and_CC human_JJ (_( Fig_NNP ._.
        5_LS )_) ._. This_DT includes_VBZ the_DT region_NN encoding_VBG the_DT 5_CD '_POS -_: 
        UTR_NNP and_CC the_DT promoter_NN region_NN ._. The_DT high_JJ
        conservation_NN between_IN the_DT mouse_NN and_CC human_JJ genes_NNS extends_VBZ at_IN
        least_JJS an_DT additional_JJ 300_CD nucleotides_NNS upstream_RB of_IN the_DT
        sequences_NNS shown_VBN in_IN Fig_NNP ._. 5_LS [_NN 35_CD ]_NN ._. Our_PRP$ data_NNS indicate_VBP that_IN
        the_DT major_JJ transcription_NN start_NN site_NN is_VBZ at_IN exactly_RB the_DT same_JJ
        sequence_NN in_IN both_DT human_NN and_CC mouse_NN (_( Fig_NNP ._. 5_LS ,_, large_JJ arrows_NNS )_) ._.
        Based_VBN on_IN these_DT new_JJ results_NNS ,_, we_PRP propose_VBP usage_NN of_IN the_DT gene_NN
        numbering_VBG system_NN shown_VBN in_IN Fig_NNP ._. 5_LS ._. For_IN mouse_NN +_NN 1_CD is_VBZ 502_CD
        nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP and_CC for_IN human_JJ +_NN 1_CD is_VBZ 472_CD
        nucleotides_NNS upstream_RB of_IN the_DT ATG_NNP ._. This_DT information_NN should_MD be_VB
        useful_JJ in_IN designing_VBG experiments_NNS to_TO analyze_VB both_DT
        transcriptional_NN and_CC translation_NN control_NN of_IN p_NN 27_CD
        Kip_NNP 1_CD expression_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cell_NNP culture_NN and_CC RNA_NNP extraction_NN
          Human_JJ breast_NN cancer_NN cell_NN lines_NNS MCF_NNP 7_CD and_CC BT_NNP 20_CD ,_, human_JJ
          fetal_JJ lung_NN cell_NN line_NN MRC_NNP 5_CD ,_, and_CC the_DT mouse_NN NIH_NNP 3_CD T_NN 3_CD cell_NN
          line_NN were_VBD maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS
          medium_NN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN ._. Total_NNP RNA_NNP was_VBD
          extracted_VBN using_VBG TRI_NNP Reagent_NNP (_( Molecular_NNP Research_NNP ,_,
          Cincinnati_NNP ,_, OH_NNP )_) and_CC stored_VBD in_IN ethanol_NN at_IN -_: 70_CD °_NN C_NNP ._.
        
        
          5_LS '_'' RLM-RACE_NNP
          5_LS '_POS RLM-RACE_NNP [_NN 37_CD 38_CD 39_CD ]_NN was_VBD performed_VBN using_VBG the_DT
          GeneRacer_NNP kit_NN (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) ._. In_IN short_JJ ,_, the_DT
          total_JJ RNA_NNP was_VBD dephosphorylated_JJ using_VBG calf_NN intestinal_NN
          phosphatase_NN then_RB decapped_JJ using_VBG tobacco_NN acid_NN
          pyrophosphatase_NN to_TO target_VB full-length_JJ messenger_NN RNAs_NNP ._. An_DT
          RNA_NNP oligonucleotide_NN was_VBD then_RB ligated_JJ to_TO the_DT full-length_JJ ,_,
          decapped_JJ mRNAs_NNS and_CC reverse_VB transcription_NN was_VBD performed_VBN
          using_VBG random_JJ primers_NNS ._. PCR_NNP was_VBD done_VBN to_TO amplify_VB the_DT
          resultant_JJ cDNAs_NNS using_VBG the_DT GeneRacer_NNP 5_CD '_POS primer_NN and_CC a_DT
          primer_NN consisting_VBG of_IN bases_NNS immediately_RB upstream_RB of_IN the_DT
          translation_NN start_NN site_NN of_IN the_DT 
          p_NN 27_CD Kip_NNP 1_CD gene_NN
          (_( CTTTCTCCCGGGTCTGCACGACCG_NNP for_IN human_JJ and_CC
          CTTCCTCCTCGGGCGGGTGT_NNP for_IN mouse_NN )_) ._. Nested_NNP PCR_NNP was_VBD then_RB done_VBN
          to_TO eliminate_VB the_DT possibility_NN of_IN artifacts_NNS using_VBG the_DT
          GeneRacer_NNP 5_CD '_POS nested_JJ primer_NN and_CC 
          p_NN 27_CD Kip_NNP 1_CD primers_NNS
          CACGACCGCCTCTCTCGCACTCTC_NNP for_IN human_JJ and_CC
          GGACCACCGCCTCGCCTCTC_NNP for_IN mouse_NN (_( see_VB Figs_NNP ._. 1_LS and_CC 2_LS )_) ._.
        
        
          Cloning_NNP and_CC sequencing_VBG
          The_DT RACE_NNP nested_JJ PCR_NNP products_NNS were_VBD cloned_VBN into_IN the_DT
          pCR_NN 4_CD Blunt-_NNP TOPO_NNP vector_NN using_VBG a_DT TOPO-cloning_NNP kit_NN
          (_( Invitrogen_NNP )_) ._. DNA_NNP obtained_VBD from_IN the_DT resultant_JJ colonies_NNS
          was_VBD sequenced_JJ with_IN the_DT USB_NNP Sequenase_NNP version_NN 2_CD ._. 0_CD DNA_NNP
          Sequencing_NNP kit_NN (_( Amersham_NNP ,_, Cleveland_NNP ,_, OH_NNP )_) using_VBG T_NN 3_CD and_CC T_NN 7_CD
          primers_NNS ._.
        
        
          Ribonuclease_NNP protection_NN assay_NN
          For_IN the_DT ribonuclease_NN protection_NN assays_NNS ,_, probes_NNS were_VBD
          made_VBN using_VBG the_DT MAXIscript_NNP kit_NN (_( Ambion_NNP ,_, Austin_NNP ,_, TX_NNP )_) ,_,
          32_CD P-CTP_NNP ,_, and_CC T_NN 7_CD RNA_NNP polymerase_NN ._. DNA_NNP from_IN the_DT RACE_NNP nested_JJ
          PCR_NNP clone_NN containing_VBG the_DT human_JJ 
          p_NN 27_CD Kip_NNP 1_CD sequence_NN from_IN -_: 472_CD to_TO -_: 17_CD
          or_CC the_DT mouse_NN 
          p_NN 27_CD Kip_NNP 1_CD sequence_NN from_IN -_: 502_CD to_TO -_: 17_CD
          was_VBD linearized_JJ with_IN Pme_NNP I_PRP and_CC used_VBN as_IN a_DT template_NN for_IN
          probe_NN synthesis_NN ._. Numbering_NNP of_IN these_DT DNA_NNP sequences_NNS was_VBD
          assigned_VBN using_VBG +_NN 1_CD as_IN the_DT translation_NN start_NN site_NN ._. After_IN
          gel_NN purification_NN of_IN the_DT probe_NN ,_, the_DT assay_NN was_VBD carried_VBN out_IN
          using_VBG the_DT HybSpeed_NNP RPA_NNP kit_NN (_( Ambion_NNP )_) ._. Total_NNP RNA_NNP was_VBD
          co-precipitated_JJ with_IN the_DT labeled_VBN probe_NN followed_VBN by_IN
          denaturation_NN and_CC hybridization_NN ._. Following_VBG digestion_NN with_IN
          RNase_NNP A_DT /_NN T_NN 1_CD ,_, the_DT protected_VBN RNAs_NNP were_VBD precipitated_VBD and_CC run_VB
          on_IN a_DT 4_CD %_NN denaturing_VBG polyacrylamide_NN gel_NN and_CC detected_VBN by_IN
          autoradiography_NN ._.
        
      
    
  
